Li-Hua Xiang1,2, Yan Fang1,2, Jing Wan1,2, Guang Xu1,2, Ming-Hua Yao1,2, Shi-Si Ding1,2, Hui Liu1,2, Rong Wu3,4. 1. Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301, Yanchangzhong Road, Shanghai, 200072, China. 2. Ultrasound Research and Education Institute, Tongji University School of Medicine, No. 301, Yanchangzhong Road, Shanghai, 200072, China. 3. Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, No. 301, Yanchangzhong Road, Shanghai, 200072, China. wurong7111@163.com. 4. Department of Ultrasound, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China. wurong7111@163.com.
Abstract
OBJECTIVES: To analyze the diagnostic value of adding SWE to MRI for the diagnosis of clinically significant prostate cancer with false-negative MRI results. METHODS: This was a retrospective study of 367 patients who underwent MRI, SWE, and prostate biopsy between March 2016 and November 2018 at the Shanghai Tenth People's Hospital. Serum prostate-specific antigen (PSA) and free PSA (fPSA) were measured preoperatively. Diagnostic value and accuracy was determined for MRI alone and MRI + SWE using the receiver operator characteristic curve (ROC) analysis. RESULTS: MRI misdiagnosed 17.9% (21/117) clinically significant prostate cancers, including 15 lesions in the peripheral zone and 6 in the central zone. Both qualitative and quantitative SWE could help detect 66.7% (10/15) significant prostate cancers with false-negative MRI, but there was no association with the Gleason score (p > 0.05). When considering the sextant of the peripheral zone, a significant association was not seen with histopathology in qualitative SWE (p = 0.071) and quantitative SWE (p = 0.598). Among age, PSA, fPSA, volume of the prostate gland, fPSA/PSA, and PSAD, only PSAD (p = 0.019) was associated with SWE results in patients with negative MRI. CONCLUSIONS: Adding SWE to MRI in patients with negative MRI for prostate examination could allow the correct diagnosis of additional patients and reduce the false-negative rate. KEY POINTS: • MRI plays an important role in clinically significant prostate cancers diagnosis. • SWE plays an important role in clinically significant prostate cancers with negative MRI. • Adding SWE to MRI in patients with negative MRI for prostate examination could allow the correct diagnosis of additional patients and reduce the false-negative rate.
OBJECTIVES: To analyze the diagnostic value of adding SWE to MRI for the diagnosis of clinically significant prostate cancer with false-negative MRI results. METHODS: This was a retrospective study of 367 patients who underwent MRI, SWE, and prostate biopsy between March 2016 and November 2018 at the Shanghai Tenth People's Hospital. Serum prostate-specific antigen (PSA) and free PSA (fPSA) were measured preoperatively. Diagnostic value and accuracy was determined for MRI alone and MRI + SWE using the receiver operator characteristic curve (ROC) analysis. RESULTS: MRI misdiagnosed 17.9% (21/117) clinically significant prostate cancers, including 15 lesions in the peripheral zone and 6 in the central zone. Both qualitative and quantitative SWE could help detect 66.7% (10/15) significant prostate cancers with false-negative MRI, but there was no association with the Gleason score (p > 0.05). When considering the sextant of the peripheral zone, a significant association was not seen with histopathology in qualitative SWE (p = 0.071) and quantitative SWE (p = 0.598). Among age, PSA, fPSA, volume of the prostate gland, fPSA/PSA, and PSAD, only PSAD (p = 0.019) was associated with SWE results in patients with negative MRI. CONCLUSIONS: Adding SWE to MRI in patients with negative MRI for prostate examination could allow the correct diagnosis of additional patients and reduce the false-negative rate. KEY POINTS: • MRI plays an important role in clinically significant prostate cancers diagnosis. • SWE plays an important role in clinically significant prostate cancers with negative MRI. • Adding SWE to MRI in patients with negative MRI for prostate examination could allow the correct diagnosis of additional patients and reduce the false-negative rate.
Entities:
Keywords:
Biopsy; Magnetic resonance imaging; Prostate cancer
Authors: Martijn G Schouten; Marloes van der Leest; Morgan Pokorny; Martijn Hoogenboom; Jelle O Barentsz; Les C Thompson; Jurgen J Fütterer Journal: Eur Urol Date: 2017-01-04 Impact factor: 20.096
Authors: M Z Zuo; W L Zhao; C G Wei; C Y Zhang; R Wen; Y F Gu; M J Li; Y Y Zhang; J F Wu; X Li; J K Shen Journal: Zhonghua Yi Xue Za Zhi Date: 2017-12-19
Authors: Marko Brock; Christian von Bodman; Rein Jüri Palisaar; Björn Löppenberg; Florian Sommerer; Thomas Deix; Joachim Noldus; Thilo Eggert Journal: J Urol Date: 2012-04-11 Impact factor: 7.450
Authors: Kenneth Hoyt; Benjamin Castaneda; Man Zhang; Priya Nigwekar; P Anthony di Sant'agnese; Jean V Joseph; John Strang; Deborah J Rubens; Kevin J Parker Journal: Cancer Biomark Date: 2008 Impact factor: 4.388
Authors: Satheesh Krishna; Matthew McInnes; Christopher Lim; Robert Lim; Shaheed W Hakim; Trevor A Flood; Nicola Schieda Journal: AJR Am J Roentgenol Date: 2017-10-05 Impact factor: 3.959
Authors: Jean-Michel Correas; Ethan J Halpern; Richard G Barr; Sangeet Ghai; Jochen Walz; Sylvain Bodard; Charles Dariane; Jean de la Rosette Journal: World J Urol Date: 2020-04-18 Impact factor: 4.226